FDA Requires Rare Vision-Loss Warning on GLP-1 Drugs

What the warning says

November 12, 2026, 1:45 a.m. Central time.

The Food and Drug Administration is requiring a new warning on GLP-1 medicines about a potential increased risk of a rare eye condition that can cause permanent vision loss.

The warning applies to the class of medications used for diabetes and weight management, including Ozempic and Wegovy, as well as Mounjaro and Zepbound. The agency’s November 9 safety communication describes a possible increased risk, not a certainty that a patient will develop the condition.

A rare condition and the evidence

The condition, called non-arteritic anterior ischemic optic neuropathy or NAION, involves reduced blood flow to the front of the optic nerve. It can cause sudden, painless loss of vision, usually in one eye.

In an analysis of 126 randomized trials, the FDA identified 15 probable cases: 10 among people taking GLP-1 drugs and five among those taking a placebo. The agency calculated rates of 6.4 and 3.8 cases per 100,000 person-years respectively; person-years account for both the number of people and how long they were followed.

The FDA said the underlying cause is not fully understood and that existing risk factors, including diabetes and high blood pressure, can complicate interpretation of reports. Other studies produced differing comparisons.

What patients should do

The FDA says patients who experience sudden painless vision loss, blind spots, color distortion or other visual changes should contact a health professional right away. It says anyone who has experienced NAION should discuss with their clinician whether to continue or stop treatment.

The agency’s communication includes medicines with different approved uses. Patients should discuss individual benefits and risks with their own prescriber; the warning does not mean everyone taking these drugs will experience vision problems.